bevacizumab + sorafenib

Bevacizumab + sorafenib is an investigational combination therapy consisting of two distinct anticancer agents with complementary mechanisms of action. Bevacizumab is a humanized monoclonal antibody that targets and neutralizes vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis—the formation of new blood vessels essential for tumor growth. Sorafenib is a small molecule multikinase inhibitor that blocks several intracellular and cell surface kinases involved in tumor cell proliferation and angiogenesis, including RAF kinases, VEGF receptors (VEGFR-1/2/3), platelet-derived growth factor receptor beta (PDGFR-β), FLT3, c-KIT, and RET. The rationale for combining these agents is to achieve more comprehensive inhibition of angiogenic pathways in cancer treatment. This combination has been studied primarily in advanced hepatocellular carcinoma (HCC) as well as other solid tumors such as ovarian cancer[1][8]. However, clinical trials have reported increased toxicity without clear evidence of superior efficacy compared to standard therapies.

Brand names

Nexavar

Other names

bevacizumab and sorafenibsorafenib plus bevacizumab